Clinical Efficacy Of Qiangxin Solution Combined With Sakubatril Valsartan In The Treatment Of HFpEF(Syndrome Of Water Overflowing Due To Yang Deficiency)

Objective: To observe the effects of Qiangxin Solution on NT-pro BNP,some cardiac ultrasound indices(LVEF,E/A ratio,E/e’ ratio),Chinese medicine symptoms and other related indices in the treatment of patients with heart failure with preserved ejection fraction(Syndrome of water overflowing due to yang deficiency),and to explore the effectiveness and safety of Qiangxin Solution in the treatment of patients with heart failure with preserved ejection fraction(Syndrome of water overflowing due to yang deficiency).To provide a theoretical basis for the clinical use of this formula.Methods: From December 2021 to December 2022,60 patients diagnosed with heart failure with preserved ejection fraction(Syndrome of water overflowing due to yang deficiency)were collected from the inpatient and outpatient departments of the Department of Cardiology,Xiangyang Traditional Chinese Medicine Hospital,and divided into 30 patients in the control group and 30 patients in the treatment group according to digital randomization.The control group was treated with sakubatril valsartan sodium tablets orally,while the treatment group was treated with Qiangxin Solution on top of the control group for a period of 2 months.To observe the changes in NT-pro BNP,some cardiac ultrasound indices(LVEF,E/A ratio,E/e’ ratio),Chinese medicine symptoms and other related indices in both groups before and after treatment,and to evaluate the efficacy and safety of cardiac strengthening solution.Results: The blood pressure and heart rate of the two groups before and after treatment were analysed:(1)Comparison between groups: the systolic blood pressure,diastolic blood pressure and heart rate of the two groups before treatment were comparable(P>0.05);the differences in systolic blood pressure and diastolic blood pressure between the two groups after treatment were statistically significant(P<0.05),and the efficacy of the treatment group was better than that of the control group,and there was no significant difference in the improvement of heart rate between the two groups after treatment(P>0.05).(2)Comparison within groups: the differences in systolic blood pressure,diastolic blood pressure and heart rate between the two groups before and after treatment were statistically significant(P<0.05),and all showed significant improvement after treatment.The BNP of patients in both groups before and after treatment was analysed:(1)between-group comparison: the difference in BNP between the two groups before treatment was comparable(P>0.05);the difference in BNP between the two groups after treatment was statistically significant(P<0.05),and the treatment group had better efficacy than the control group.(2)Comparison within groups:the differences in BNP between the two groups before and after treatment were statistically significant(P<0.05),and the values of BNP decreased after treatment.Some of the cardiac ultrasound indexes were analysed before and after treatment in the two groups:(1)Comparison between groups: before treatment,the differences between the two groups in LVEF,E/A and E/e’ were comparable(P>0.05);after treatment,the P values of the above three indexes in the two groups were >0.05 after the sample t-test,indicating that there was no difference between the two groups in LVEF,E/A and E/ e’indexes were not different.(2)Comparison within groups: the differences between the two groups of patients in these two indicators,E/A and E/e’,before and after treatment were statistically significant(P<0.05),and both groups were able to improve the above two indicators;the differences between the two groups of patients in LVEF before and after treatment were not statistically significant,with P-values >0.05,suggesting that the treatment in both groups did not significantly improve LVEF.The total TCM syndrome points of the two groups of patients before and after treatment were analysed:(1)between-group comparison: before treatment,the differences in the TCM syndrome points of the two groups of patients were comparable(P>0.05);after treatment,the differences in the total TCM syndrome points of the two groups of patients were statistically significant(P<0.05),and the improvement effect was more significant in the treatment group.(2)Comparison within groups: the differences between the two groups before and after treatment were statistically significant(P<0.05),suggesting that there was a significant decrease in the TCM symptom scores in both groups after treatment.For the efficacy of the two groups after treatment by Fisher exact probability method exact test,the P value was 0.025,P<0.05,suggesting a statistically significant difference between the two groups.The effective rate of the treatment group was 90%,and the effective rate of the treatment group on TCM symptoms was significantly higher than that of the control group.After the exact test of NYHA cardiac function in both groups by Fisher’s exact probability method,the P value was 0.013,P<0.05,suggesting that the difference between the two groups was statistically significant.The total effective rate of the treatment group was 96.67%,and the effective rate of the treatment group was significantly higher than that of the control group.Conclusion:1.Qiangxin Solution combined with sakubatril valsartan treatment was more effective in reducing systolic blood pressure,diastolic blood pressure and BNP than sakubatril valsartan alone in treating HFp EF(Syndrome of water overflowing due to yang deficiency).2.Qiangxin Solution combined with sakubatril valsartan could significantly improve the clinical Chinese medicine symptoms in patients with HFp EF(Syndrome of water overflowing due to yang deficiency).It is also safe.3.Treatment with Qiangxin Solution combined with sakubatril valsartan can significantly improve the NYHA cardiac function classification inpatients with HFp EF(Syndrome of water overflowing due to yang deficiency).4.Qiangxin Solution combined with sakubatril valsartan provides an effective clinical basis for the treatment of HFp EF(Syndrome of water overflowing due to yang deficiency)and provides a new idea and method for the combined treatment of ejection fraction-preserved heart failure by Chinese and Western medicine.